We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
-5.15%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$325M
AUM Growth
+$83.1M
Cap. Flow
-$7.26M
Cap. Flow %
-2.23%
Top 10 Hldgs %
48.17%
Holding
91
New
22
Increased
30
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$9.77M
2
VCYT icon
Veracyte
VCYT
+$5.92M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$4.32M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$4.3M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$3.98M

Top Sells

Rank Stock Value
1
LONA
LeonaBio Inc
LONA
+$27M
2
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$14.2M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$9.72M
4
ITOS
iTeos Therapeutics
ITOS
+$4.47M
5
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.45M

Sector Composition

Rank Sector Weight
1 Healthcare 65.69%
2 Miscellaneous 34.31%
3 Financials 0%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$490B
$45.5M 14.02%
+162,500
New +$50.4M
ITCI
2
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$17.9M 5.52%
313,962
+5,143
+2% +$292K
XBI icon
3
CALL
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$15.5M 4.76%
208,300
-91,700
-31% -$6.88M
BLU
4
DELISTED
BELLUS Health Inc.
BLU
$14.4M 4.45%
1,562,957
+327,173
+26% +$2.68M
VCYT icon
5
Veracyte
VCYT
$3.41B
$14.3M 4.4%
718,789
+293,235
+69% +$5.92M
CERS icon
6
Cerus
CERS
$512M
$11.1M 3.41%
2,093,861
+695,461
+50% +$3.47M
MRUS
7
DELISTED
Merus
MRUS
$10.6M 3.27%
469,113
+144,394
+44% +$3.01M
AVXL icon
8
PUT
Anavex Life Sciences
AVXL
$264M
$9.18M 2.83%
+917,100
New +$8.69M
MORF
9
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$9.09M 2.8%
418,660
+349,951
+509% +$9.77M
VERU icon
10
PUT
Veru
VERU
$44M
$8.82M 2.72%
+78,040
New +$9.06M
RXDX
11
PUT
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$8.52M 2.62%
+301,700
New +$8.74M
CTIC
12
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$8.24M 2.54%
1,380,111
-869,889
-39% -$4.45M
ACRS icon
13
Aclaris Therapeutics
ACRS
$892M
$7.53M 2.32%
539,545
+264,212
+96% +$3.7M
COGT icon
14
Cogent Biosciences
COGT
$6.12B
$7.41M 2.28%
820,954
+247,255
+43% +$1.69M
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
$7.22M 2.22%
40,787
+29,831
+272% +$4.3M
XENE icon
16
Xenon Pharmaceuticals
XENE
$5.77B
$7.08M 2.18%
232,630
+131,549
+130% +$3.98M
KRYS icon
17
Krystal Biotech
KRYS
$10.4B
$6.91M 2.13%
105,277
+58,788
+126% +$3.66M
MRTX
18
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.77M 2.09%
+100,900
New +$6.42M
APLS
19
DELISTED
Apellis Pharmaceuticals
APLS
$5.87M 1.81%
129,795
+24,427
+23% +$1.11M
ALNY icon
20
CALL
Alnylam Pharmaceuticals
ALNY
$34.8B
$5.83M 1.8%
+40,000
New +$5.67M
HZNP
21
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.76M 1.77%
72,187
+4,745
+7% +$449K
ORIC icon
22
Oric Pharmaceuticals
ORIC
$1.31B
$4.85M 1.49%
+1,082,304
New +$4.32M
CFRX
23
PUT
DELISTED
ContraFect Corporation
CFRX
$4.8M 1.48%
+19,536
New +$5.52M
BIIB icon
24
Biogen
BIIB
$31.4B
$4.25M 1.31%
20,825
+10,577
+103% +$2.16M
INSM icon
25
Insmed
INSM
$27.3B
$4.19M 1.29%
212,482
+110,415
+108% +$2.31M
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Silverarc Capital Management held 91 positions worth $325M, up 34% from $242M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Silverarc Capital Management's Q2 2022 filing shows 22 new, 30 increased, 16 reduced and 21 closed positions. Its largest new stake was Oric Pharmaceuticals: 1,082,304 shares worth $4.85M. The largest sale was LeonaBio Inc, an estimated $27M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.

  • Silverarc Capital Management's largest Q2 2022 buy was Oric Pharmaceuticals: 1,082,304 shares worth $4.85M.
  • Silverarc Capital Management added most to Morphic Holding, Inc. Common Stock in Q2 2022, an estimated $9.77M increase.
  • Silverarc Capital Management's biggest Q2 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $9.72M.
  • Silverarc Capital Management fully exited LeonaBio Inc in Q2 2022, selling an estimated $27M.
  • Silverarc Capital Management's ten largest holdings make up 48% of its $325M portfolio in Q2 2022.
  • Silverarc Capital Management opened 22 new positions and closed 21 in Q2 2022.
  • Silverarc Capital Management's portfolio value rose 34% quarter-over-quarter to $325M.

Based on Silverarc Capital Management's 13F filing for Q2 2022, filed 25 Jul 2022.